---
schema_version: "secwatch.filing_event.v1"
accession: "0001638833-22-000132"
form_type: "8-K"
ticker: "SGRY"
cik: "0001638833"
company_name: "Surgery Partners, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:48:56.188759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Surgery Partners Q3 revenue +11% to $620.6M, Adj EBITDA $96.2M, reaffirms FY guidance

## Summary
- Revenue $620.6M (+11.0% YoY); same-facility revenue +5.1% (cases +3.3%, rev/case +1.8%).
- Net loss $25.0M vs $22.9M loss; Adjusted EBITDA $96.2M (+26% YoY); margin 15.5% (+180bps).
- Reaffirms FY2022 Adj EBITDA $375M-$385M; revenue $2.5-$2.55B.
- YTD deployed $240M on acquisitions (12 facilities) at sub-8x EBITDA; added 150+ physicians.
- Liquidity ~$500M ($154.8M cash + $342M revolver capacity); net debt/EBITDA 6.0x.

## SEC filing metadata
- accession: 0001638833-22-000132
- form_type: 8-K
- ticker: SGRY
- cik: 0001638833
- company_name: Surgery Partners, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/sgry-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001638833-22-000132
- JSON: https://secwatch.observer/filing/0001638833-22-000132.json
- Plain text: https://secwatch.observer/filing/0001638833-22-000132.txt

## Key facts
- Earnings Releases
  Surgery Partners, Inc. reported Full year 2022 results: revenue $2.5 billion to $2.55 billion. Guidance reaffirmed.
  - Period: Full year 2022
  - Revenue: $2.5 billion to $2.55 billion
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company reaffirms projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm
- Earnings Releases
  Surgery Partners, Inc. reported Third quarter ended September 30, 2022 results: revenue $620.6 million, net income -$25.0 million.
  - Period: Third quarter ended September 30, 2022
  - Revenue: $620.6 million
  - Net income: -$25.0 million
  - Result: reported results
  source text: Revenue for the third quarter of 2022 increased 11.0% to $620.6 million from $559.2 million for the third quarter of 2021. Same-facility revenues for the third quarter of 2022 increased 5.1% from the same period last year, with an increase in revenue per case of 1.8% and an increase in same-facility cases of 3.3%. For the third quarter of 2022, the Company’s net 1 loss attributable to common stockholders and Adjusted EBITDA was $25.0 million and $96.2 million, respectively, compared to $22.9 million and $76.4 million, respectively, for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000132/0001638833-22-000132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.